Skip to main
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 33%
Buy 24%
Hold 38%
Sell 5%
Strong Sell 0%

Bulls say

Biogen is poised for growth due to the success of its commercial execution, with strong revenue beats in the first quarter of 2026 and a favorable tax rate. Its newer franchises are also showing promise, with potential for further growth in the future. Key upcoming catalysts and strategic initiatives, such as the APLS acquisition and pipeline updates, will likely contribute to its long-term success and justify a BUY rating. However, potential risks include slower-than-expected sales ramp and competition from other biopharmaceutical companies.

Bears say

Biogen is facing several challenges and uncertainties, such as declining revenue from its multiple sclerosis franchise, competition in the market, and potential pipeline setbacks. While the company is actively pursuing treatments for high unmet needs in neurodegenerative diseases, it remains to be seen if these therapies will be successful in the market. Additionally, the company's sustainability initiatives and employee engagement are commendable, but may not necessarily translate into financial success. Overall, there are concerns about the long-term growth potential of the company and risks associated with its pipeline.

Biogen (BIIB) has been analyzed by 21 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 24% recommend Buy, 38% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 21 analysts, Biogen (BIIB) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $208, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $208, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.